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Abstract
Background The urea cycle defect argininosuccinate
lyase (ASL) deficiency has a large spectrum of
presentations from highly severe to asymptomatic.
Enzyme activity assays in red blood cells or fibroblasts,
although diagnostic of the deficiency, fail to discrimi-
nate between severe, mild or asymptomatic cases.
Mutation/phenotype correlation studies are needed to
characterize the effects of individual mutations on the
activity of the enzyme.
Methods Bacterial in-vitro expression studies allowed the
enzyme analysis of purified mutant ASL proteins p.I100T
(c.299 T>C), p.V178M (c.532 G>A), p.E189G (c.566A>
G), p.Q286R (c.857A>G), p.K315E (c.943A>G), p.R379C
(c.1135 C>T) and p.R385C (c.1153 C>T) in comparison to
the wildtype protein.
Results In the bacterial in-vitro expression system, ASL
wild-type protein was successfully expressed. The known
classical p.Q286R, the novel classical p.K315E and the
known mutations p.I100T, p.E189G and p.R385C, which
all have been linked to a mild phenotype, showed no
significant residual activity. There was some enzyme
activity detected with the p.V178M (5 % of wild-type)
and p.R379C (10 % of wild-type) mutations in which Km
values for argininosuccinic acid differed significantly from
the wild-type ASL protein.
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Conclusion The bacterially expressed enzymes proved that
the mutations found in patients and studied here indeed are
detrimental. However, as in the case of red cell ASL
activity assays, some mutations found in genetically
homozygous patients with mild presentations resulted in
virtual loss of enzyme activity in the bacterial system,
suggesting a more protective environment for the mutant
enzyme in the liver than in the heterologous expression
system and/or in the highly dilute assays utilized here.
Introduction
Argininosuccinate lyase (ASL, EC 4.3.2.1, MIM *608310)
catalyzes the cleavage of argininosuccinate to fumarate and
arginine which is further metabolized to ornithine and urea
in the urea cycle. Additionally, it is involved in the
synthesis of arginine as substrate of the nitric oxide (NO)
synthase to yield citrulline and NO. ASL was first purified
and characterized from human liver (Palekar and Mantagos
1981), is expressed highly in liver and kidney and at much
lower levels in many other tissues and cells including red
blood cells and fibroblasts (O'Brien and Barr 1981).
ASL deficiency, also named argininosuccinic aciduria
(ASLD, MIM #207900), is inherited in an autosomal-
recessive trait (Brusilow and Horwich 2001). This is the
second most common urea cycle disorder with an incidence
of approximately 1 in 70,000 live births (Levy et al. 1984).
The phenotype is highly variable ranging from acute
neonatal-onset with severe hyperammonemic encephalopa-
thy, often causing severe mental retardation in surviving
patients to subacute and late-onset forms with less severe
symptoms such as mild mental retardation and learning
disabilities (Kleijer et al. 2002). Progressive liver disease is
one of the long-term complications which is poorly
understood (Zimmermann et al. 1986).
ASL deficiency is diagnosed by hyperammonemia and
increased levels of argininosuccinic acid and its anhydrides
in blood and urine. The diagnosis can be confirmed by
genetic means both on the RNA and DNA level. So far
more than 40 known disease-causing mutations have been
reported (Al-Sayed et al. 2005; Barbosa et al. 1991a;
Christodoulou et al. 2006; Kleijer et al. 2002; Linnebank et
al. 2000, 2002; Mercimek-Mahmutoglu et al. 2010;
Sampaleanu et al. 2001; Tanaka et al. 2002; Trevisson et
al. 2007; Walker et al. 1990).
As an alternative to mutation analysis or in cases with no
detected mutations in the ASL gene, ASL activity can be
determined in erythrocytes and skin fibroblasts by two
types of assay. In the direct assay, the immediate reaction
products arginine or fumarate, respectively, are determined
in-vitro (Nuzum and Snodgrass 1976). In the indirect assay,
ASL activity is estimated from the amount of radioactive
citrulline incorporated into acid precipitable proteins in
cultured fibroblasts (Kleijer et al. 2002). In previous studies
with patients presenting mild or asymptomatic ASLD, red
cell and fibroblast activity assays tended to reveal higher
activity decreases than citrulline incorporation assays in
fibroblasts, which in some cases gave even normal results
(Ficicioglu et al. 2009; Kleijer et al. 2002). This discrep-
ancy may, at least in part, be due to an overestimation of
ASL activity in the indirect assay (Kleijer et al. 2002) and/
or to a limited accuracy of the direct enzyme assay due to
the low ASL activity in fibroblasts.
Previous studies showed that recombinant ASL amena-
ble to kinetic and structural analysis may be obtained in
high yield in a bacterial expression system (Sampaleanu et
al. 2001). In order to better understand the clinical
heterogeneity, we expressed mutant proteins from patients
with variable severity of ASLD in E. coli and determined
the enzymatic activity of ASL in-vitro.
Material and methods
Patients
Information was collected from 28 homozygous patients of
Turkish, German, Italian, Austrian and Finish origin. This
study focuses on the seven homozygous genotypes found in
this cohort of which six were already reported (Barbosa et
al. 1991a; Linnebank et al. 2002; Mercimek-Mahmutoglu et
al. 2010; Walker et al. 1997) and one novel mutation. Two
mutations were associated with neonatal-onset and five
with late-onset or asymptomatic ASLD. Among the patients
with neonatal-onset, two carried the known mutation
c.857A>G (p.Q286R) (Walker et al. 1990). In another
patient who was detected by newborn screening the novel
change c.943A>G (p.K315E) was found in a homozygous
state. This patient was consequently treated from the second
week of life and never experienced a hyperammonemic
crisis but still showed a poor neurological outcome with
severe psychomotor retardation.
In the group of patients with late-onset ASLD, 12
patients carried the mutation c.1153 C>T (p.R385C) and
had mild to moderate symptoms (Keskinen et al. 2008;
Kleijer et al. 2002). Similarly, four patients with the
c.299 T>C (p.I100T) mutation with late-onset ASLD had
only a learning disability (Keskinen et al. 2008). In two
more patients with late-onset ASLD, c.1135 C>T (p.
R379C) and c.532 G>A (p.V178M) mutations were
identified. In addition, the latter mutation and the known
mutation c.566A>G (p.E189G) were found by newborn
screening in three and two children, respectively, who have
remained asymptomatic so far (Mercimek-Mahmutoglu et al.
2010).
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The study was approved by the Ethics Committee of the
University of Münster. All parents signed a written
informed consent form prior to mutation analysis. All
mutant alleles detected in patients from this study were
identified in parents confirming their carrier status.
Mutation analysis
Genomic DNA was purified from whole blood using the
QIAamp DNA blood kit (Qiagen, Hilden, Germany). For
mutation screening, exon-wise PCR amplification was
carried out as described previously (Linnebank et al. 2002).
Construction of wildtype and mutant expression plasmids
ASL wild-type cDNA was prepared from control cultured
fibroblasts (RNeasy Mini Kit, Invitrogen, Groningen, The
Netherlands). Amplification of the ASL full-length cDNA
as initial template was performed using oligonucleotides 5′-
ATGTGGATCCCCTCGGAGGTGAGTGGGACC (forward)
and 5′- ACGTGGTACCCTAGGCCTGCTGTGCCTGCAG
(reverse) which carried a BamHI and KpnI restriction site.
After denaturation at 94 °C, amplification with PWO-
polymerase was accomplished at an annealing temperature
of 65 °C for 35 cycles. The amplified fragments were
purified and subcloned into TA cloning vector pCR2.1
(Invitrogen). Plasmids were control-sequenced using the
ABI Prism 3700 DNA sequencer (Applied Biosystems,
Foster City, CA), digested by BamHI and KpnI and ligated
into the expression vector pQE30 (Qiagen). This plasmid
introduces the 6-His containing tag at the N-terminus of the
polypeptide (sequence then reads Met-Arg-Gly-Ser-6xHis-
ASL protein). The pQE30 plasmid containing wildtype ASL
was used for in-vitro site-directed mutagenesis (GeneTailor
Site-Directed Mutagenesis System, Invitrogen) following the
manufacturer’s instructions. Oligonucleotide primers carry-
ing the desired mutations are indicated in Table 1. Mutagen-
esis was performed at an annealing temperature of 55 °C for
29 cycles using Platinum Taq High Fidelity DNA Polymer-
ase (Invitrogen). Mutant plasmids grown in and isolated
from DH5α™-T1® E. coli (Invitrogen) were control
sequenced.
Expression of human wildtype and mutant ASL in E. coli
Purified and sequence-controlled plasmids were trans-
formed into E. coli host strain M15 [pREP4] (Qiagen).
Positive clones of each mutant and wild-type ASL were
grown in LB media containing 50 μg/ml ampicillin and
25 μg/ml kanamycin overnight at 37 °C. 5 ml of this
overnight culture were inoculated in 100 ml fresh LB
medium containing identical concentrations of antibiotics.
Expression of recombinant protein was induced by adding
isopropyl thiogalactoside (IPTG) to a final concentration of
1 mM when OD600 of the culture reached 0.5 to 0.8 and
temperature was lowered to 25 °C. On the following
morning, cells were harvested by centrifugation and the
pellets suspended in each 3 ml lysis buffer (300 mM NaCl,
200 mM NaH2PO4, 5 mM imidazol, pH 8) and lysed by 10
cycles sonification 10 sec (Kontes Micro-Ultrasonic Cell
Disruptor, Kontes, Vineland, N.J., U.S.A.). Cell lysates
were then centrifuged at 4 °C and 11.000 rpm for 30 min
and the supernatant used for purification.
Purification of recombinant wild-type and mutant ASL
proteins
Expressed wildtype and mutant ASL proteins were purified
under native conditions using nickel agarose affinity
columns according to the manufacturer’s instructions (The
QIAexpressionist, Qiagen). In brief, polypropylene col-
umns were prepared containing each 1.5 ml nickel agarose
Table 1 Details of the mutations investigated in this study, clinical course of disease and results of enzymatic analysis of mutated recombinant
proteins
Nucleotide level WT c.299 T>C c.532 G>A c.566 A>G c.857 A>G c.943 A>G c.1135 C>T c.1153 C>T
Protein level p.I100T p.V178M p.E189G p.Q286R p.K315E p.R379C p.R385C
Exon 4 7 7 11 12 14 15
Clinical course mild mild mild severe severe mild mild
ASL activity a 4227 20 208 41 23 5 280 3
Vmax
b 12112 n.d. 254 n.d. n.d. n.d. 488 n.d.
Km (mM)
b 2.6 n.d. 0.2 n.d. n.d. n.d. 0.23 n.d.
a ASL activity (mU/mg protein) measured under standard conditions using 13.6 mM argininosuccinate: activities are mean values of four and two
independent experiments for the WT and mutant proteins, respectively, each measured in triplicate.
b Vmax (mU/mg protein) and Km was only measured in proteins with residual activities above 5%. Vmax and Km were extrapolated from the linear
part of the double-reciprocal plots of two experiments.
n.d.: not determined
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and loaded with about 3 ml supernatant. Columns were
then gently mixed on ice using a rotary shaker for 90 min.
Then, each column was washed five times using each 4 ml
washing buffer (300 mM NaCl, 200 mM NaH2PO4, 10 mM
imidazole, pH 8). Then, recombinant proteins were eluted
in fractions using four times 1 ml elution buffer (50 mM
NaPi, 300 mM NaCl, 250 mM imidazol, no protease
inhibitors, pH7). Purified proteins were immediately frozen
in 50% glycerol at −80 °C. Ten %-SDS-PAGE analysis was
carried out using 15 μl of eluate to estimate the purity of
the proteins. In order to analyse the tetramer stability of the
ASL proteins we performed an 11.5% native PAGE. For the
silver staining 15 μl of recombinant proteins, for the
Western blot 0.5 μl of recombinant proteins and 8 μg
human liver-protein were loaded. As marker we used the
NativeMark™ Unstained Protein Standard from Invitrogen.
For immunoblotting, the membrane was blocked over
night (4°C) with 5% non-fat dried milk in T-TBS (T-TBS:
20 mM TRIS, 137 mM NaCl, 0.1% Tween-20, pH 8.3) and
then incubated for 2 h at room temperature with rabbit
antiserum ASL, diluted 1:1000 in 1% non fat dried milk in
T-TBS. The membrane was then washed thrice in T-TBS
and incubated in a 1:5000 dilution of peroxidase conjugate
anti-rabbit IgG (Amersham) in T-TBS (1 % non fat dried
milk) for 1 h at room temperature. Blots were washed
finally in T-TBS and bound ASL antibodies visualized onto
Amersham Hyperfilm ECL by chemiluminescence (ECL
kit, Amersham) with different exposure times. The film was
scanned on a conventional scanner.
The concentration of purified proteins was determined
with the Bio-Rad DC Protein Assay (Bio-Rad Nr 500–
0116) using BSA (Sigma-Aldrich, Buchs, Switzerland) as
standard. Protein concentrations were corrected with the
blank (protein elution puffer and 50 % glycerol).
Determination of enzyme activity
ASL activity of recombinant proteins was determined
spectrophotometrically using a coupled assay with arginase
and measuring urea production as described (Ceriotti and
Spandrio 1963). The reaction was initiated by adding 50 μl
ASL protein solution (8–16 μg enzyme) to 100 μl
argininosuccinate (13.6 mM final concentration) in water
and 100 μl arginase (50 units) (both Sigma-Aldrich) in
66.7 mM Na-phosphate (at pH 7.5) and stopped after 30
min at 37 °C by the addition of perchloric acid 2% final
concentration. Enzyme activities of wild-type and mutant
proteins are expressed as mU/mg protein. Vmax and Km,
were determined by extrapolation from double-reciprocal
plots of 1/v versus 1/[argininosuccinate] at argininosucci-
nate concentrations of 0.544 mM, 0.272 mM, 0.181 mM,
0.136 mM and 0.068 mM, respectively. All assays were
carried out in triplicate.
Structural analysis of the ASL protein
Structural analysis was performed on the basis of the
crystal structure of the ASL mutant Q286R obtained
from the Protein Data Bank PDB Entry 1 K62 (http://
www.rcsb.org/pdb/). The reconstitution of the ASL tet-
ramers was carried out in CHIMERA (Pettersen et al.
2004) using the data of the PDB file. The location of one
argininosuccinate substrate molecule was superimposed to
the model based on its known location in the highly
homologous duck delta-2-crystallin (PDB Entry 1DCN).
The Pymol software with the hollow utility was used to
produce the pictures (The PyMOL Molecular Graphics
System Version 1.3, Schrödinger, LLC).
Results
Expression and enzymatic characterization of recombinant
ASL proteins
Recombinant wild-type and all seven different mutant ASL
proteins were obtained with a purity of >90% as judged by
SDS-PAGE (Fig. 1). Silver staining and western blot of
native polyacrylamide gel of the wild-type and mutant ASL
proteins Q286R and R385C illustrates the purity of the
investigated proteins and shows that the vast majority of
investigated ASL proteins are present in the tetrameric form
(Fig. 2).
Activity of recombinant wildtype ASL protein from four
independent experiments was 4227±321 mU/ mg protein
(mean±SD; triplicate measurements) under standard assay
conditions (13.6 mM argininosuccinate). At tenfold higher
substrate concentration, activity was decreased by 18%
indicating substrate inhibition. Further measurements at
varying substrate concentrations (range 0.068–13.6 mM)
yielded nonlinear double-reciprocal plots of 1/v versus 1/
[argininosuccinate] with marked deviation from linearity
already at standard assay conditions. Vmax and Km,
extrapolated from the linear part of the double-reciprocal
plots of two experiments were 12112 mU / mg protein and
2.6 mM, respectively (Table 1).
Recombinant proteins carrying the mutations p.Q286C
and p.K315E which were associated with severe ASL
deficiency and the mild mutations p.I100T, p.E189G and p.
R385C exhibited less than 1% of the wildtype activity
under standard assay conditions, respectively, and were not
subjected to further kinetic analysis. There was also no
activity detectable with reducing the argininosuccinate
concentration to 7.8 mM.
In contrast, recombinant proteins carrying the mild
mutations p.V178M and p.R379C yielded residual activi-
ties of 4.9% and 6.6% under standard assay conditions,
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respectively. Both wildtype and mutant proteins p.V178M
and p.R379C were inhibited by higher substrate concen-
trations. Vmax and Km values of the mutant enzymes were
between one and two orders of magnitude lower than the
corresponding values of the wildtype enzyme (Table 1).
Localization of mutations in the homotetrameric protein
Localization of the mutated amino acids in the quaternary
structure of the enzyme revealed two distinct distribution
patterns. Amino acids I100, Q286, R379 and R385 are in
close vicinity to the active site and/or the argininosuccinate
binding pocket, whereas amino acids V178, E189 and
K315 are all at the contact surface between different
monomers of the tetramer (Fig. 3).
Discussion
ASLD exhibits a highly variable phenotypic pattern ranging
from life-threatening neonatal onset to mild developmental
delay and learning disabilities to asymptomatic phenotype.
Unfortunately, with the exception of the severe neonatal-
onset cases which generally have a poor prognosis, long-
term outcome is difficult to predict. Widhalm et al. followed
12 patients with biochemically confirmed ASLD identified
by newborn screening. All patients were treated with
arginine supplementation and, some with protein restricted
diet (Widhalm et al. 1992). All patients showed normal
intellectual and psychomotor development, however the
degree of residual ASL activity was not reported. More
recently, Shih and coworkers followed another 13 patients
with ASLD identified by newborn screening and confirmed
by enzymatic analysis in red blood cell hemolysates and/or
fibroblast extracts (Ficicioglu et al. 2009). In their long-
term follow-up study, the outcome of patients with
neonatal-onset and late-onset disease identified by selective
screening was compared: patients identified by newborn
screening had higher enzyme activities as measured by the
14C-citrulline incorporation assay and had a better long-
term outcome than patients identified by selective screen-
ing. In fact, with one exception 14C-citrulline incorporation
in the newborn screening group was not different from a
control group. In contrast, red blood cells and fibroblasts of
patients from both the newborn screening group and the
late-onset group exhibited markedly decreased enzyme
activities ranging from not detectable to 10–20% of
controls by the direct enzyme assay method. Similar
discrepancies between the two assays had previously been
observed by Kleijer et al. in five patients with late-onset
disease (Kleijer et al. 2002). These authors also showed that
the relative residual activity in the citrulline incorporation
assay decreased with increasing citrulline concentration,
probably because ASL activity is not the rate-limiting step
in the citrulline incorporation assay. Nevertheless, the
discrepancy between the two assays remained even at near
saturating citrulline concentrations.
There is a known broad genetic heterogeneity at the ASL
locus, which might determine diversity in residual enzyme
function. The activity of mutant ASL proteins has been
assessed in human fibroblasts (Kleijer et al. 2002),
eukaryotic COS-1 cells (Howell et al. 1998; Walker et al.
1997), erythrocytes (Bastone et al. 1990; Trevisson et al.
2007) and rat hepatocytes (Bastone et al. 1990) but
bacterial in-vitro expression has only been performed for a
few mutations (Sampaleanu et al. 2001; Yu et al. 2001).
The aim of our study was to test whether varying levels
of residual enzyme activity contribute to the severity of the
clinical course of ASLD. It should be noted that we
investigated recombinant proteins that comprised, in addi-
tion to the wildtype or mutant ASL sequence, another three
amino acids (Arg-Gly-Ser) as well as the 6xHis-tag.
However, the relatively high activity in-vitro, albeit some-
what lower than previously reported in human liver
Fig. 1 SDS-PAGE analysis of 15 μl of in E. coli expressed wild-type
and mutant ASL proteins investigated in the present study illustrating
a level of purity of>90%. kDa: Kilo-Daltons; WT: wild-type
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Fig. 2 Native polyacrylamide gel electrophoresis of the wild-type and
mutant ASL proteins Q286R and R385C. The silver staining
illustrates the purity of the investigated proteins and the western blot
confirm that the vast majority of recombinant proteins are present in
the tetrameric form
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(Palekar and Mantagos 1981) or recombinantly expressed
in bacteria (Yu et al. 2001), suggests that the added amino
acid sequence to N-terminus does not interfere with the
protein folding and formation of the intact ASL homote-
tramer. In contrast to previous literature (Palekar and
Mantagos 1981; Yu et al. 2001) we found a non-
hyperbolic dependency of the ASL activity on the [argini-
nosuccinate] and 20-fold higher Km of the wild-type
protein. Native PAGE of the wild-type and mutant ASL
proteins Q286R and R385C shows that the vast majority of
these recombinant proteins are present in the tetrameric
form and excludes cold-dissociation as explanation. The
discrepancies of absolute activity levels in our study and
those reported in the literature may be due to different
activity assay used; e.g., we did not continuously monitor
fumarate in our assay.
The mutant p.Q286R was used as negative control
because it has been identified before in neonatal-onset
patients (Barbosa et al. 1991b; Trevisson et al. 2007) and
demonstrated only minimal residual ASL activity in trans-
fected COS-1 cells (Walker et al. 1997) and only 3.0%
residual activity in E. coli (Yu et al. 2001). In our assay, this
mutation did not exhibit any residual activity. Likewise, the
novel mutation c.943A>G (p.K315E), identified in a
Turkish patient detected by newborn screening who showed
severe retardation despite absence of hyperammonemic
episodes, yielded no relevant residual ASL activity.
In a pair of siblings, who were identified by newborn
screening and remained asymptomatic after initiation of
treatment prior to onset of symptoms, the mutation c.566A>
G (p.E189G) was found in a homozygous state (Mercimek-
Mahmutoglu et al. 2010). Since no other cases with this
mutation are known to date, the natural course of this
specific mutation remains unknown. As in p.K315E muta-
tion, there was only irrelevant low residual activity in the
bacterial in-vitro expression. Thus, the cause of the signif-
icantly better outcome in comparison to the one patient
affected by mutant p.K315E remains obscure.
Another four mutations investigated in this study (p.
I100T, p.V178M, p.R379C, p.R385C) have been described
in relation to mild phenotype of ASLD (Linnebank et al.
2002). Other than in the direct assay (0%), enzymatic
activities of 7-20% were identified by the indirect assay in
fibroblasts from patients who were homozygous for p.
R385C mutation (Kleijer et al. 2002). However, the
bacterial in-vitro expression of p.R385C mutation yielded
no relevant residual activity. Similarly, p.I100T mutation
did not result in relevant residual activity but there are no
data from enzyme measurements in other cells for
comparison.
A striking difference was found for protein variants p.
V178M and p.R379C which were both identified in
patients with a mild phenotype (Kleijer et al. 2002). For
mutant p.V178M, residual ASL activity in fibroblasts in a
direct assay and in an indirect assay yielded relevant
residual activity (<10% and 8%, respectively) (Kleijer et
al. 2002). In accordance with these findings, mutant p.
V178M showed a similar level of residual activity (5% of
wildtype) in the bacterial in-vitro expression. Similarly, the
residual enzyme activity of mutant p.R379C measured in
the bacterial in-vitro expression system was 10% of wild-
type activity which is only slightly lower than the ASL
activity in fibroblasts as measured by the indirect assay (15-
28%; (Kleijer et al. 2002)).
Measurement of ASL activity in cultured skin fibroblasts
has served as diagnostic means in patients with ASLD. The
indirect enzyme assay has been proven to be superior to the
Fig. 3 View on the ASL-homotetramer with one argininosuccinate
depicted in its binding-cavity. Two of the oligomer are drawn in ribbon
view (orange and mauve) one in surface (green) and one in ribbon and
transparent surface (blue). Amino acids of interest in this study are
shown in red. The center of the figure show an overview of the
homotetramer, on two different point of view ( rotation of about 90
degree on an vertical axis). (AS=argininosuccinate)
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direct assay (Ficicioglu et al. 2009; Kleijer et al. 2002).
However, ASL activity in late-onset patients has been
shown to be as low as in neonatal-onset patients indicating
that the level of residual activity in fibroblasts has only
limited prognostic value (McInnes et al. 1984). In contrast,
increased levels of residual activity were only found in
patients with late-onset ASLD. In line with this, residual
activity levels of the mutant proteins p.V178M and p.
R379C in the bacterial in-vitro expression system are
consistent with the data obtained from cultured fibroblasts.
However, other mutant proteins associated with a mild
phenotype were not distinguishable from severely defective
proteins. Thus, the expression system presented here does
not reliably predict a mild phenotype of ASLD.
Part of the variability of the clinical courses in ASLD
might be explained by tissue specific expression of the ASL
protein as suggested by the finding of substantial ASL
activity in brain tissues of neonatal-onset patients with loss
of activity in liver (Glick et al. 1976; Perry et al. 1980).
Besides tissue specific expression, DNA methylation has
been shown to influence the level of ASL gene expression.
This mechanism seems to be of particular importance for
the different levels of ASL protein activity and ASL mRNA
synthesis in adult and fetal rat liver (Renouf et al. 1998).
However, the role of this developmental regulation mech-
anism in tissue specific expression in the mature human
organism is as yet unclear.
The localization of the mutated amino acids within the
ASL homotetramer allows us to speculate on their
functional consequences. Mutants located near the argini-
nosuccinate binding pocket are likely to affect ASL enzyme
activity to varying degrees. Likewise, mutants that affect
the formation of the monomer surface may lead to
heterodimer instability ultimately affecting homotetramer
stability. Thus, the mutant proteins investigated in this study
may lead to an impairment of ASL function by different
mechanisms.
It is essential to make a note of the fact that our
experiments only reflect patients who are homozygous for a
certain mutation. In cases of compound heterozygosity
extensive intragenic complementation is known to contrib-
ute to different degrees of ASLD severity (Howell et al.
1998; McInnes et al. 1984). The effect of this mechanism
varies with each set of mutations.
In summary, the bacterial in-vitro expression of ASL
mutants is feasible and might detect variants with only
partial impairment of ASL activity. However, the sensitivity
of the enzyme analysis of mutant proteins derived from this
artificial system does not allow for a reliable prediction of
all ASL mutants associated with mild ASLD. Insofar, there
is still a lack of an unfailing prognostic factor for patients
with ASLD and the basis of their clinical heterogeneity
remains to be fully elucidated.
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